Tasigna works by blocking the proteins needed to activate and grow cancer cells, and while it can stop cancer cells from growing and spreading, it does not cause harm to non-cancerous cells. However, the drug has been associated with serious and life-threatening conditions.
Patients who are treated with Tasigna may develop a dangerous and rapidly progressing plaque buildup in their arteries. If you were treated with the drug and suffered serious adverse health consequences then you can file a lawsuit from tasignalawyer.com/.
This condition, called atherosclerosis, can result in tissue death and gangrene, heart attack and stroke, amputations, and wrongful death.
It’s also approved for the treatment of chronic period and rapid phase Ph+ CML in adults that are intolerant or resistant to earlier treatment.The medication now includes a black box warning regarding the possibility of QT prolongation, and it will be just a heart rhythm problem that may lead to sudden departure.
Nevertheless, that the Tasigna lawsuits claims that Novartis needs to also have provided strong warnings concerning the possible artherosclerosis side effects, which might result in a stroke, stroke, heart attack, amputations or passing.
The instance increases allegations like those exhibited in many of Tasigna suits being chased by people nationally, suggesting that the medical community weren’t adequately warned about the potential for heart attacks, strokes, and the demand for amputations and departure.
The McWilliams as well as other plaintiffs assert that Novartis has been alert to their Tasigna stroke hazard since at the very least 2010, after reports by clinical researchers who identified unwanted effects inpatients who comprised hardening and narrowing of blood vessels which supply blood to the arms and legs, brain and heart.
Novartis issued a warning to both Canadian caregivers and also the Canadian people after an evaluation by Health Canada; this states drug regulatory agency. But, no very similar warning or telling has been given to patients and physicians at the U.S., the litigation asserts.
Patients who developed atherosclerosis after receiving treatment with Tasigna are seeking justice through the legal system. Lawsuits continue to be filed on behalf of patients who allege they were not adequately warned about the dangers of Tasigna atherosclerosis and its severe and potentially life-threatening side effects.